The US Food and Drug Administration (FDA) has approved Sanofi-Aventis’ short-acting insulin Admelog (insulin lispro injection) for improved control of blood sugar levels in people suffering from diabetes mellitus.

Admelog is indicated for type 1 diabetes mellitus patients aged three years and above, and to treat adults with type 2 diabetes mellitus.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug can be administered through subcutaneous injection or infusion, or by intravenous infusion.

Its dosing will depend on the administration route, individual metabolic needs, blood glucose monitoring results and glycaemic control goal.

Sanofi-Aventis submitted an application that was partially based on the FDA’s safety and effectiveness findings for Humalog (insulin lispro injection).

“This is particularly important for drugs like insulin that are taken by millions of Americans every day for a patient’s lifetime to manage a chronic disease.”

The application also included Admelog-specific data from two Phase III clinical trials conducted in about 500 patients to validate the product’s safety and efficacy for approved uses.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During the trials, the most common Admelog-related adverse reactions were found to be hypoglycaemia, itching, and rash.

FDA Commissioner Scott Gottlieb said: “One of my key policy efforts is increasing competition in the market for prescription drugs and helping facilitate the entry of lower-cost alternatives.

“This is particularly important for drugs like insulin that are taken by millions of Americans every day for a patient’s lifetime to manage a chronic disease.

“In the coming months, we’ll be taking additional policy steps to help to make sure patients continue to benefit from improved access to lower cost, safe and effective alternatives to brand-name drugs approved through the agency’s abbreviated pathways.”